Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. - Wikidata - awgldk - TriplyDB

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

http://www.wikidata.org/entity/Q35848726

about

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents Safety and efficacy of azacitidine in myelodysplastic syndromes An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents Decitabine in the treatment of myelodysplastic syndromes Monitoring the effect of belinostat in solid tumors by H4 acetylation Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics Update on rational targeted therapy in AML Molecular Pathways Bridging Frontotemporal Lobar Degeneration and Psychiatric Disorders Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatments New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome Childhood acute myeloid leukaemia Predicting response to epigenetic therapy Feasibility of therapy with hypomethylating agents in patients with renal insufficiency Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia Integrative modeling of multi-platform genomic data under the framework of mediation analysis.A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).Decitabine: a review of its use in older patients with acute myeloid leukaemia.Successful treatment with low-dose decitabine in acute myelogenous leukemia in elderly patients over 80 years old: Five case reports Myelodysplastic syndromes: Contemporary review and how we treat.Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target.Large-scale analysis of DNA methylation in chronic lymphocytic leukemia DNA hypomethylation in cancer cells.Epigenetic therapies in MDS and AML Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.

P2860

Q21198868-EE76E247-95F5-45A1-9AEF-2194B038EC63 Q24596561-1F9258D4-30AC-4752-A9AC-7A43D8E3172B Q24622700-3FCB7773-D46A-4C84-B64B-1C274AE957DC Q24633763-5AB1D926-4934-428D-954C-C22D0161E3EE Q24641906-2974366D-9B03-4DA5-8F90-3B99CB657ACE Q24644030-F27DC605-B5DC-44DE-8E56-212B91A75E75 Q26744080-FBE592E0-8F2D-4BD6-9341-31AA66E95D98 Q26749421-7C499725-8B6C-43A2-A091-DF6F635D86B4 Q26766152-B15EC71E-CDF8-486E-B5BC-6B282907AAA7 Q26766487-6B7D18C9-11B6-499C-856B-7582F9F2E671 Q26770391-3B7AAA10-3FA2-4CEA-8DE1-CA1B5F96F4C3 Q26828724-69D2F1D0-64F4-4961-899A-095FB441C26D Q26829132-585EFD99-7C73-4D13-91D4-93FBEDC72122 Q27005960-2BEE8289-36CF-4D1C-A819-CA2B12370A04 Q27027751-0301DC48-E5F5-427F-BB1A-0F9A8E678297 Q28283836-84F97585-A265-4AC6-8DF7-C744E41BED14 Q28294892-4B94D619-69AE-480F-8989-B0CDD3376DCA Q28385690-1B0AE7BC-41D3-4829-9AE6-291083478305 Q29394054-58EF3B89-D176-4404-BF94-C297173E6FC5 Q30860315-9A328998-5162-4246-A868-AD79BB9BFAB7 Q33267359-E73435A3-2D26-4D95-9BCE-E9AE15B3EFDB Q33393266-BDD79992-DFDA-4787-9D10-8EE0EC825FE4 Q33395173-4AFD5F55-9CF5-4778-9F27-76F3AF5BB359 Q33407030-D90D4346-DCC4-49C3-90B3-8346F3747BD0 Q33407141-AFC8A6D3-5883-4F4E-B122-08A3BFF4FDBB Q33429195-745A2D27-20EC-449B-ADD7-1143F3388733 Q33558088-D343C5C3-8BEE-4A26-80E2-F18FCE629921 Q33665187-A703263C-1F55-4000-91D7-68A348EE0B25 Q33741025-4F361580-07DF-489A-A26B-E1E86496EE14 Q33775647-0E79FBDA-B1CB-4A53-9962-9367C4D6D7A8 Q33841988-9E3ED11F-EC45-4F40-8C36-8711224B478F Q33843955-041EA8ED-BFBF-4B0D-92CF-4399BDB45576 Q33844751-8F4DE408-D810-454F-9D1F-709215EC80B2 Q33847891-3148A9A2-3EEC-450F-AC30-56895A0CB3D8 Q33859881-069A2886-4627-4ED2-A3A3-8B0DE6DC333A Q33862334-ACB65752-F8CE-4D78-9C8A-B14C62F43C2A Q33863567-EEA6AD07-820D-492D-8C91-4950786F399C Q33863925-A9E65AD8-0AC7-4D7B-A54A-C6D714CB0276 Q33929924-0A12B591-B681-4102-8A43-6D92B261EE4D Q33939624-4E00DCE1-D4DC-43EA-8D9E-D861B6BB8B6A

P2860

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

http://www.wikidata.org/entity/Q35848726

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Phase 1/2 study of the combina ...... cid in patients with leukemia.

@ast

Phase 1/2 study of the combina ...... cid in patients with leukemia.

@en

type

label

Phase 1/2 study of the combina ...... cid in patients with leukemia.

@ast

Phase 1/2 study of the combina ...... cid in patients with leukemia.

@en

prefLabel

Phase 1/2 study of the combina ...... cid in patients with leukemia.

@ast

Phase 1/2 study of the combina ...... cid in patients with leukemia.

@en

P1433

Q35848726-C145A53C-9876-4337-AD2D-FE153191C663

P1476

Q35848726-61E09B95-77A8-470D-8A22-952ADEEE5CF5

P2093

Q35848726-1BCEEE48-0B74-4528-85E2-7D2EDFDC2B41

Q35848726-260969E2-8080-4AE6-9A8F-19C65B58885D

Q35848726-37980999-6AC5-4F55-8CA2-B19534CE5203

Q35848726-3E5529D7-9137-4FCF-B01B-140F4EF4C567

Q35848726-434CD8CD-056A-4EFB-AA7D-0FA1A1378BBB

Q35848726-4FD77528-255F-4548-9F54-56C162088FE0

Q35848726-5491A1DE-B193-4CC7-96BD-8208A9950314

Q35848726-6941FE28-2A1A-4355-80DE-3F0995CDFB2A

Q35848726-72F6ACE3-2F83-41BA-9F7C-FCC384758998

Q35848726-BBACA25D-60F0-4A69-9437-AC597A1C15E6

P2860

Q35848726-124AF579-298E-40DF-8E9A-AA573BB14BA8

Q35848726-12931325-DB16-4846-B68B-C33C5207FA2A

Q35848726-1966BFC6-9544-4684-8D2C-6645FE533398

Q35848726-1D040605-9D19-431C-BEDA-4BD3B095409A

Q35848726-2A16B9AF-98BA-451C-9884-1057871D9181

Q35848726-36A98A5F-AEE4-41F7-9CC9-3232F0CBD550

Q35848726-3731EA0F-68D2-422D-A164-9586299C254D

Q35848726-54A3B167-95F7-48AA-B4A9-86699577773A

Q35848726-5C0D8F4D-EDAD-422B-948D-2726BE469086

Q35848726-638DE980-287D-4B00-B5C6-004532BF8914

P304

Q35848726-FEFC557E-A79B-45FC-A3BB-42A782C8BE64

P31

Q35848726-2A4F9909-FFF4-4A54-8F37-2BA152549DDE

P356

Q35848726-162FB8F2-EEFC-4614-9EE0-25BBCB4DAA98

P407

Q35848726-CD36B638-E4C1-498B-A376-D26FBFB90C13

P433

Q35848726-140A5DC9-4502-447F-AFC1-845E0F285DE1

P478

Q35848726-8349C963-593C-4284-9253-22F61482DCA4

P50

Q35848726-51D2A95D-A14B-4C7F-8575-DB4A6BFD4D81

Q35848726-5352D5F5-EC5E-4FD1-AFC1-1169A6E1526F

Q35848726-58A7D7AF-2DA0-4DF1-AB5E-9EF4BB9554B3

Q35848726-6A68CE9A-8BFB-432A-B555-9F3032E13032

Q35848726-857700FD-A943-48EB-804D-25BB213BA1A0

Q35848726-D427BFB7-1E43-4FED-8408-9FCECB608384

Q35848726-DA4EA6C2-785F-4637-9765-EB34F0BD49C3

Q35848726-EBB739C4-A03C-40D9-884D-084651E76050

Q35848726-F9388104-1A0B-4A64-8886-A3973E7EFA17

Q35848726-FB013C7C-10C6-4E3B-99EB-A37ED1B6B703

P577

Q35848726-99621095-50A6-4EC0-87C7-AEC1D8E7A72B

P5875

Q35848726-FAD32513-C878-4C25-AB32-82DA309C5B2D

P698

Q35848726-1519D741-8E19-4602-A185-0C9A736E2EA0

P921

Q35848726-8EA067AC-9392-49C0-BCAB-CC087D251038

Q35848726-E5C084F7-917E-440E-9327-8DFEBDA69173

P932

Q35848726-0D6F6407-7884-45F9-AE4D-C9898BAE585B

P356

BLOOD-2006-03-009142

P1433

P1476

Phase 1/2 study of the combina ...... cid in patients with leukemia.

@en

P2093

Blanca Sanchez-Gonzalez

http://www.w3.org/2001/XMLSchema#string

Carlos Bueso-Ramos

http://www.w3.org/2001/XMLSchema#string

Charles Koller

http://www.w3.org/2001/XMLSchema#string

Elihu Estey

http://www.w3.org/2001/XMLSchema#string

Gary Rosner

http://www.w3.org/2001/XMLSchema#string

Hui Yang

http://www.w3.org/2001/XMLSchema#string

Jackie Fiorentino

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Issa

http://www.w3.org/2001/XMLSchema#string

Lianchun Xiao

http://www.w3.org/2001/XMLSchema#string

Michael Rytting

http://www.w3.org/2001/XMLSchema#string

P2860

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

DNA methylation in health and disease.

DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia.

Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia.

Valproic acid for the treatment of pediatric malignant glioma.

Relationships between chromatin organization and DNA methylation in determining gene expression.

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.

P304

3271-3279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2006-03-009142

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Eduardo Cortes

Hagop Kantarjian

William G Wierda

Srdan Verstovsek

Guillermo Garcia-Manero

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6903484

http://www.w3.org/2001/XMLSchema#string

P698

16882711

http://www.w3.org/2001/XMLSchema#string

P921

P932

1895437

http://www.w3.org/2001/XMLSchema#string